Certara (NASDAQ:CERT) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Certara (NASDAQ:CERT) issued its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.01), Zacks reports. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara updated its FY 2025 guidance to 0.420-0.460 EPS.

Certara Trading Down 0.4 %

CERT stock traded down $0.05 during trading on Wednesday, hitting $12.33. The company had a trading volume of 1,222,313 shares, compared to its average volume of 1,274,044. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a 50 day simple moving average of $12.36 and a 200-day simple moving average of $11.63. The firm has a market capitalization of $1.98 billion, a P/E ratio of -61.65, a PEG ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CERT. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Barclays reduced their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.